Epstein-Barr Virus Vaccine Research
The National Institute of Allergy and Infectious Diseases (NIAID) is conducting a research study aimed at stopping the spread of the Epstein-Barr virus (EBV), the main cause of mono. Join our compensated study and further EBV vaccine research today!
Fast Facts
18 - 29 Years Old
Compensation Provided
Conducted in Bethesda, MD
About Our Research Study
Epstein-Barr virus (EBV) infects more than 90% of the world’s population, and when adolescents and young adults contract the virus they are at risk of experiencing serious health complications like developing mono or certain cancers. Currently, there is no vaccine that prevents or treats EBV infection.
Join researchers and help stop the spread of EBV! Participation in this research study may inform future treatments. Compensation provided up to $2220.
Epstein-Barr virus (EBV) infects more than 90% of the world’s population, and when adolescents and young adults contract the virus they are at risk of experiencing serious health complications like developing mono or certain cancers. Currently, there is no vaccine that prevents or treats EBV infection.
Join researchers and help stop the spread of EBV! Participation in this research study may inform future treatments. Compensation provided up to $2220.
Additional Information
You may qualify for this study if you meet the following criteria.
Eligibility Criteria:
- 18 – 29 years old
- In general good health (no major medical conditions)
- No ongoing use of immunosuppressive medications
- No substance use disorder
Once enrolled, this study involves:
- In-person and virtual visits
- 3 doses of experimental EBV vaccine
- Participant safety evaluation and monitoring